Cantharidin use among pediatric dermatologists in the treatment of molluscum contagiosum

Pediatr Dermatol. 2009 Jul-Aug;26(4):405-8. doi: 10.1111/j.1525-1470.2008.00860.x.

Abstract

Cantharidin is cited often in the dermatology and pediatric literature as a valuable treatment option for molluscum contagiosum (MC). However, there have been no prospective, randomized, vehicle-controlled trials that have been able to quantify cantharidin's efficacy in MC. The purpose of this study was to determine the breadth of usage of cantharidin, most frequently used protocols, and common side effects seen with use of cantharidin. An eighteen question survey was administered to the Society of Pediatric Dermatology. The survey sought to evaluate treatments used in MC and experiences with cantharidin including: protocol, side effects, specific products used, and satisfaction with cantharidin. A total of 300 surveys were distributed via email, 101 surveys were initiated, and 95 (94%) of these were completed. Cantharidin, imiquimod, benign neglect, curettage, cryotherapy, and retinoids were the most common approaches to pediatric MC reported by respondents. Ninety-two percent of respondents reported satisfaction with cantharidin's efficacy, but 79% reported side effects, with discomfort/pain and blistering being the most common. Cantharidin is a common modality in the treatment of MC among pediatric dermatologists. While efficacy data is still lacking, subjective satisfaction with cantharidin is reported. Cantharidin remains a viable treatment option for children with MC.

MeSH terms

  • Cantharidin / adverse effects
  • Cantharidin / therapeutic use*
  • Child
  • Clinical Protocols
  • Dermatology / methods*
  • Drug Compounding
  • Drug Industry
  • Drug Utilization
  • Humans
  • Molluscum Contagiosum / drug therapy*
  • Office Visits / statistics & numerical data
  • Pediatrics / methods*
  • Pharmacy
  • Treatment Outcome

Substances

  • Cantharidin